Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004078 · ClinicalTrials.gov registry record · Phase 2

Irinotecan in Treating Children With Refractory Solid Tumors

A Phase 2 study, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 2
Development phase
181
Enrollment target

NCT00004078: Completed Phase 2 study, sponsored by Children's Oncology Group.

NCT00004078 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004078, a Phase 2 study, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
181 participants
Enrollment target

Study Summary

This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Interventions

  • DRUG irinotecan hydrochloride

Trial Details

FieldValue
Enrollment Target 181 participants
Start Date 1999-10
Phase Phase 2
Children's Oncology Group

342 total trials

What the finished NCT00004078 record still lists

NCT00004078 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).

The record links to 0 conditions, and to 1 intervention - of which irinotecan hydrochloride is the first listed.

NCT00004078 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00004078 about?

NCT00004078 is a clinical study titled "Irinotecan in Treating Children With Refractory Solid Tumors". This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

What is the current status of trial NCT00004078?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 1999-10.

What interventions are being tested in trial NCT00004078?

The interventions under investigation include: irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00004078?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00004078's enrollment target sits among peer trials

181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04578392 · 181 participants · NA

    MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

  • NCT05597891 · 181 participants · NA

    Endovascular Engineering ENGULF Study

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00004078, the US trial registry maintained by the National Library of Medicine. NCT00004078 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.